Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.

Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC)
AIDS. 2013 27 (5): 803-13

PMID: 23719350 · DOI:10.1097/QAD.0b013e32835cb997

MeSH Terms (26)

Adenine Alkynes Anti-HIV Agents Antiretroviral Therapy, Highly Active Benzoxazines Cohort Studies Cyclopropanes Deoxycytidine Dideoxynucleosides Drug Combinations Emtricitabine Europe HIV-1 HIV Infections HIV Protease Inhibitors HIV Seropositivity Humans Lamivudine Lopinavir Nevirapine Organophosphonates Reverse Transcriptase Inhibitors Risk Factors Tenofovir Time Factors United States

Connections (1)

This publication is referenced by other Labnodes entities: